Cargando…
Surface Levels of CD20 Determine Anti-CD20 Antibodies Mediated Cell Death In Vitro
BACKGROUND: The sensitivity of human Burkitt's lymphoma cells to rituximab (Rtx) and tositumomab (Tst) was assessed on cells expressing different levels of CD20 on surface. Cells that harbor low CD20 levels may resists against therapeutics response to CD20-specific antibodies. We postulated tha...
Autores principales: | Singh, Vijay, Gupta, Damodar, Arora, Rajesh, Tripathi, Rajendra Prashad, Almasan, Alexandru, Macklis, Roger M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4217761/ https://www.ncbi.nlm.nih.gov/pubmed/25364827 http://dx.doi.org/10.1371/journal.pone.0111113 |
Ejemplares similares
-
Development of Novel Anti-Cd20 Monoclonal Antibodies and Modulation in Cd20 Levels on Cell Surface: Looking to Improve Immunotherapy Response
por: Singh, Vijay, et al.
Publicado: (2015) -
Monoclonal antibodies targeting CD20
por: Chang, Chien-Hsing, et al.
Publicado: (2013) -
Generation of CD20-specific TCRs for TCR gene therapy of CD20(low) B-cell malignancies insusceptible to CD20-targeting antibodies
por: Jahn, Lorenz, et al.
Publicado: (2016) -
Response to: Monoclonal antibodies targeting CD20
por: Klein, Christian, et al.
Publicado: (2013) -
Novel chimerized IgA CD20 antibodies: Improving neutrophil activation against CD20-positive malignancies
por: Evers, Mitchell, et al.
Publicado: (2020)